Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Negoro E, Yamauchi T, Fukuhara N, Yamamoto K, Uchida T, Izutsu K, Maruyama D, Terui Y, Nakajima H, Ando K, Suehiro Y, Choi I, Kanemura N, Nakamura N, Yamamoto G, Maeda Y, Shibayama H, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Kim WS, Tobinai K. Negoro E, et al. Among authors: tobinai k. J Clin Exp Hematop. 2023;63(2):108-120. doi: 10.3960/jslrt.23005. J Clin Exp Hematop. 2023. PMID: 37380467 Free PMC article. Clinical Trial.
Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.
Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S, Uchida T, Kishi K, Tanaka Y, Kohno A, Kasai M, Higuchi M, Kasai M, Mori S, Fukuda T, Izutsu K, Sao H, Ishikawa T, Ichinohe T, Takeuchi K, Tajima K, Tanosaki R, Harada M, Taniguchi S, Tobinai K, Hotta T, Takaue Y. Kim SW, et al. Among authors: tobinai k. Blood. 2006 Jul 1;108(1):382-9. doi: 10.1182/blood-2005-02-0596. Epub 2006 Mar 7. Blood. 2006. PMID: 16522821 Free article.
Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori S, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y. Maruyama D, et al. Among authors: tobinai k. Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41. doi: 10.1016/j.bbmt.2007.04.004. Epub 2007 May 29. Biol Blood Marrow Transplant. 2007. PMID: 17640597 Free article.
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, Watanabe T, Maruyama D, Morishima Y, Kagami Y, Taji H, Minami H, Itoh K, Nakata M, Hotta T. Ogawa Y, et al. Among authors: tobinai k. Cancer Sci. 2008 Jan;99(1):140-4. doi: 10.1111/j.1349-7006.2007.00638.x. Epub 2007 Oct 27. Cancer Sci. 2008. PMID: 17970782 Free article. Clinical Trial.
468 results